On June 29, Liquidia Technologies rose 6.32% overnight, trading at $83.11 USD/share, with Turnover of $115,300.
Within the Pharmacy sector where Liquidia Technologies belongs, the overall sector performance was mixed. Among individual stocks, Eli Lilly up 1.98%, Johnson & Johnson down 0.18%, Merck down 0.23%, Axsome Therapeutics up 0%, Pfizer up 0%.
Liquidia Corporation is a biopharmaceutical company focused on the development, manufacturing, and commercialization of products to address unmet patient needs, with a current focus on pulmonary arterial hypertension treatment. Its lead product YUTREPIA has been commercially launched, with the most recent quarter delivering net product sales of approximately $130 million and more than 4,500 unique patient prescriptions received.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments